

Interlace Medical Sponsors the World Congress Leadership Summit on the Business of Women's Health in Boston, Massachusetts

New Technology for Removing Submucosal Fibroids and Polyps Provides Increased Patient Satisfaction and Hospital Revenue

Framingham, MA., June 8, 2010 - Interlace Medical will be showcasing its [MyoSure™](#) Hysteroscopic Tissue Removal System for the treatment of [submucosal fibroids](#) at the World Congress Leadership Summit on the Business of Women's Health June 9-11th at the Lenox Hotel in Boston. During this summit, hospital executives will learn how adding the MyoSure Hysteroscopic Tissue Removal System to their women's health service line will increase revenue and patient satisfaction.

The MyoSure system enables physicians to quickly remove fibroids with a single step, incision-less treatment alternative while avoiding the risks associated with energy-based devices. The easy-to-use device provides gynecologists with confidence, control, and a minimally invasive care option for their patients. Studies show the efficacy rate for [hysteroscopic removal of fibroids](#) is very high with close to 96 percent of patients receiving symptom resolution and less than 10 percent recurrence at five years. MyoSure is a solution for the 1.6 million patients looking for a less invasive, quicker procedure, that will not affect their busy lifestyle.

"Having a MyoSure system in place at a hospital is really a win/win situation for patients and doctors, as well as the facility," says Bill Gruber, President and CEO of Interlace Medical. "Not only are you offering patients an incision-less procedure, but doctors are using a simpler, quicker technique that is easy to learn and perform. Plus, with this system in place you are able to bring more procedural volume to your hospital thus increasing annual revenue and profit."

Doctors agree the best outcome for treating submucosal fibroids and polyps is achieved by using a device that does not rely on RF energy or non-isotonic distention medium, has a small outer diameter, and is easy to use. The MyoSure system provides patients and physicians with a safe and simple solution to [abnormal uterine bleeding](#) caused by intrauterine pathology.

About Interlace Medical

Interlace Medical is a global leader in the rapid delivery of innovative medical device solutions that improve patient outcomes, simplify physician adoption and reduce the cost of healthcare. Interlace Medical continually addresses the need for a safer, less invasive gynecological procedure by developing cost effective, technologically advanced devices that improve patient care, reduce costs, and provide procedural confidence to physicians.

The MyoSure Hysteroscopic Tissue Removal System is a new and innovative treatment that enables fast, safe, and incision-less removal of submucosal fibroids while providing effective

relief of abnormal uterine bleeding symptoms. MyoSure is an ideal treatment option for women seeking to preserve uterine form and function.

###

For additional information, visit www.myosure.com or contact:

Bill Gruber
President and CEO
Interlace Medical
bill@interlacemedical.com

Nicole M. Shugrue
Director of Marketing
Interlace Medical
nicole@interlacemedical.com